截至9月20日，睿智医药股东户数4.47万，较上期减少5.99%；人均流通股10626股，较上期增加6.37%。 2025年1月-6月，睿智医药实现营业收入5.34亿元，同比增长14.75%；归母净利润2538.21万元，同比增 长140.35%。 分红方面，睿智医药A股上市后累计派现1.80亿元。近三年，累计派现0.00元。 机构持仓方面，截止2025年6月30日，睿智医药十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股2433.19万股，持股数量较上期不变。 责任编辑：小浪快报 9月30日，睿智医药跌0.78%，成交额1.19亿元。两融数据显示，当日睿智医药获融资买入额916.92万 元，融资偿还2227.71万元，融资净买入-1310.79万元。截至9月30日，睿智医药融资融券余额合计2.03 亿元。 融资方面，睿智医药当日融资买入916.92万元。当前融资余额2.03亿元，占流通市值的3.58%，融资余 额超过近一年70%分位水平，处于较高位。 融券方面，睿智医药9月30日融券偿还5300.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量4200.00股，融券 ...

变更后的公司网址及投资者邮箱自本公告披露之日起正式启用。除上述变更 外，公司投资者联系电话、传真、联系地址均保持不变，敬请广大投资者关注。 特此公告。 睿智医药科技股份有限公司 董事会 2025 年 9 月 26 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 睿智医药科技股份有限公司（以下简称"公司"）因经营发展需要，为提升公 司形象，方便投资者、客户及社会公众及时了解和掌握公司信息，公司对官方网 站进行了全面升级改版，并对公司网址及投资者邮箱进行了变更，具体情况如下： | 变更事项 | 变更前 | 变更后 | | --- | --- | --- | | 公司网址 | www.cppt.com.cn | www.chempartner.com | | 投资者邮箱 | ir@cppt.com.cn | ir@chempartner.com | 证券代码：300149 证券简称：睿智医药 公告编号：2025-67 睿智医药科技股份有限公司 关于变更公司网址及投资者邮箱的公告 ...

Core Viewpoint - The article discusses the announcement by President Trump regarding a new round of high tariffs on various imported products, particularly focusing on the pharmaceutical industry, which will see a 100% tariff on patented and branded drugs starting October 1, 2023, significantly higher than the previous 15% agreement with Europe [1][2]. Group 1: Tariff Details and Market Reaction - The new tariffs include a 50% tariff on kitchen cabinets and bathroom sinks, a 30% tariff on imported furniture, and a 100% tariff on patented and branded drugs, with exemptions for companies that have manufacturing facilities "under construction" in the U.S. [1][2] - Following the announcement, the innovation drug index and various biotech ETFs saw declines of over 1%, with specific companies like Huahai Pharmaceutical and Baiyue Shenzhou experiencing stock price drops [2][3]. Group 2: Company Responses and Strategies - Many domestic pharmaceutical companies are assessing the impact of the new tariffs, with some indicating that their production capabilities in the U.S. may mitigate the effects. For instance, Huahai Pharmaceutical is evaluating whether its facilities meet the criteria for exemption [4][5]. - Major U.S. pharmaceutical companies like Johnson & Johnson and Eli Lilly have already invested significantly in expanding their domestic production capabilities, with Johnson & Johnson planning to invest approximately $20 billion in North Carolina and Eli Lilly announcing a $270 billion investment for new factories [3][4]. Group 3: Expert Opinions and Future Outlook - Industry experts suggest that the 100% tariff is politically motivated and may not significantly impact domestic innovative drug companies, as many already have manufacturing in the U.S. and the majority of their sales are through partnerships with multinational corporations [6][7]. - The anticipated implementation of a global drug pricing model by the U.S. government could further influence drug pricing and market dynamics, but experts believe that the overall impact on the domestic pharmaceutical industry will be limited [6][7].

机构持仓方面，截止2025年6月30日，睿智医药十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股2433.19万股，持股数量较上期不变。 责任编辑：小浪快报 9月24日，睿智医药涨0.33%，成交额1.78亿元。两融数据显示，当日睿智医药获融资买入额1489.34万 元，融资偿还1759.85万元，融资净买入-270.50万元。截至9月24日，睿智医药融资融券余额合计2.34亿 元。 截至9月20日，睿智医药股东户数4.47万，较上期减少5.99%；人均流通股10626股，较上期增加6.37%。 2025年1月-6月，睿智医药实现营业收入5.34亿元，同比增长14.75%；归母净利润2538.21万元，同比增 长140.35%。 融资方面，睿智医药当日融资买入1489.34万元。当前融资余额2.34亿元，占流通市值的3.91%，融资余 额超过近一年80%分位水平，处于高位。 分红方面，睿智医药A股上市后累计派现1.80亿元。近三年，累计派现0.00元。 融券方面，睿智医药9月24日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量9500.00股，融券余额1 ...

睿智医药9月24日披露，截至9月20日公司股东户数为44659户，较上期（9月10日）减少2847户，环比降 幅为5.99%。 证券时报·数据宝统计，截至发稿，睿智医药收盘价为11.99元，上涨0.33%，本期筹码集中以来股价累 计下跌9.17%。具体到各交易日，3次上涨，7次下跌。 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 （文章来源：证券时报网） 融资融券数据显示，该股最新（9月23日）两融余额为2.36亿元，其中，融资余额为2.36亿元，本期筹码 集中以来融资余额合计减少5315.23万元，降幅为18.37%。 公司发布的半年报数据显示，上半年公司共实现营业收入5.34亿元，同比增长14.75%，实现净利润 2538.21万元，同比增长140.35%，基本每股收益为0.0510元，加权平均净资产收益率2.07%。（数据 宝） ...

Core Viewpoint - The company, Ruizhi Pharmaceutical, has experienced a significant stock price increase of 214% over the past six months, rising from a low of 4.86 CNY per share to a high of 15.28 CNY per share, indicating a successful turnaround in the capital market [1]. Group 1: Stock Performance and Fundraising - The stock price of Ruizhi Pharmaceutical closed at 12.69 CNY per share on September 19, 2023, after previously being below 10 CNY for an extended period [1]. - The company is progressing with a private placement to raise up to approximately 316 million CNY, with the issuance price set at 5.27 CNY per share [1][2]. - The private placement will allow Jiangmen Ruilian Pharmaceutical Investment Co., Ltd. to become the controlling shareholder of Ruizhi Pharmaceutical, increasing the shareholding of the actual controller, WOO SWEE LIAN, from 21.18% to 29.66% [1]. Group 2: Financial Health and Business Operations - Ruizhi Pharmaceutical's main business includes drug discovery, development, and production services, focusing on the CRO/CDMO sector, particularly in preclinical research [3]. - The company has faced financial challenges, reporting revenues of approximately 1.327 billion CNY, 1.138 billion CNY, and 970 million CNY from 2022 to 2024, with net profits of 363 million CNY, -917 million CNY, and -226 million CNY respectively [3]. - The overall funding requirement for the company is about 1.222 billion CNY, with a funding gap of approximately 504 million CNY [4]. Group 3: Recent Developments and Future Outlook - In the first half of 2025, Ruizhi Pharmaceutical reported revenues of approximately 534 million CNY, a year-on-year increase of 14.75%, and a net profit of about 25.38 million CNY, up 140.35% [5]. - The company attributes its improved performance to the recovery of the pharmaceutical industry and effective management strategies, with expectations for continued growth [5]. - The latest private placement aims to enhance the actual controller's control over the company and demonstrate shareholder confidence in the company's future development [8].

Core Insights - The article highlights the significant stock price increase of RuiZhi Pharmaceutical (300149.SZ), which rose from a low of 4.86 CNY per share to a high of 15.28 CNY per share, marking a 214% increase over the past six months [1] - The company is progressing with a private placement to raise up to approximately 316 million CNY, with the issuance price set at 5.27 CNY per share, aimed at enhancing liquidity and repaying bank loans [2][3] Group 1: Stock Performance - RuiZhi Pharmaceutical's stock price has shown a remarkable recovery, closing at 12.69 CNY per share as of September 19, after a prolonged period below 10 CNY per share [1] - The company has experienced a significant turnaround in its stock performance, attributed to the recovery of the pharmaceutical industry and improved management strategies [5] Group 2: Fundraising and Financials - The private placement involves issuing no more than approximately 60.02 million shares, with the total fundraising amount not exceeding about 316 million CNY, which will be used to supplement working capital and repay bank loans [2][4] - RuiZhi Pharmaceutical's financial performance has been under pressure, with revenues of approximately 13.27 billion CNY, 11.38 billion CNY, and 9.7 billion CNY from 2022 to 2024, and net profits showing a decline in 2023 and 2024 [3][4] Group 3: Corporate Governance and Control - The private placement will result in RuiLian Investment becoming the controlling shareholder of RuiZhi Pharmaceutical, increasing the shareholding of its actual controller, WOO SWEE LIAN, from 21.18% to 29.66% [1][2] - The issuance aims to enhance the actual controller's control over the company and reflects shareholder confidence in the company's future development [7]

Group 1: Financial Performance and Market Strategy - The company aims to achieve significant revenue growth from the Boston laboratory, which is a key step in its global strategy, targeting increased overseas business and enhancing existing operations [2] - The company's revenue returned to a growth trajectory in the first half of the year, with profits turning positive, despite fluctuations in the stock price due to macroeconomic factors [3] - Domestic CRO service orders increased by over 40% year-on-year in the first half of the year, indicating strong market demand [5] Group 2: Operational Updates and Challenges - The company has temporarily halted operations at the Qidong large molecule production base due to a lack of improvement in the domestic CDMO market, while the Zhangjiang facility can meet current production demands [4] - The company is actively expanding its full-package service business, with multiple projects in negotiation, typically valued in the tens of millions of RMB [5] - The company is considering the acquisition of the Qidong facility based on market conditions and existing rental agreements [4] Group 3: Investor Relations and Future Plans - The company is in the process of responding to inquiries from the Shenzhen Stock Exchange regarding its refinancing efforts, which are progressing in an orderly manner [6] - The company emphasizes that its stock price is influenced by various factors, including market sentiment and economic conditions, and advises investors to be aware of investment risks [6] - The establishment of an industrial fund aims to drive business growth by investing in innovative pharmaceutical companies, ensuring business synergy with the company's operations [5]

Company Overview - Ruizhi Pharmaceutical Technology Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on January 26, 2000. It was listed on December 22, 2010. The company's main business involves pharmaceutical research and production outsourcing services, micro-ecological nutrition, and micro-ecological medicine [2] - The revenue composition of the company is as follows: 99.06% from pharmaceutical research and production outsourcing services, 0.52% from prebiotic products, 0.35% from rental income, and 0.07% from other income [2] - As of September 10, 2023, the number of shareholders is 47,500, an increase of 2.44% from the previous period, with an average of 9,989 circulating shares per person, a decrease of 2.38% [2] Financial Performance - For the first half of 2025, Ruizhi Pharmaceutical achieved operating revenue of 534 million yuan, a year-on-year increase of 14.75%. The net profit attributable to the parent company was 25.38 million yuan, representing a year-on-year growth of 140.35% [2] - The company has cumulatively distributed 180 million yuan in dividends since its A-share listing, with no dividends distributed in the past three years [3] Stock Performance - On September 19, 2023, Ruizhi Pharmaceutical's stock price decreased by 2.00%, trading at 12.74 yuan per share, with a total market capitalization of 6.344 billion yuan [1] - Year-to-date, the stock price has increased by 98.44%, but it has declined by 4.93% over the last five trading days and by 2.38% over the last 20 days. Over the last 60 days, the stock price has risen by 24.54% [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on July 29, where it recorded a net purchase of 165 million yuan [1]

（文章来源：证券日报） 证券日报网讯睿智医药9月18日在互动平台回答投资者提问时表示，美国波士顿实验室作为公司全球化 布局的重要一环，已于2025年9月10日正式投入运营。这将显著增强公司在美国市场的业务拓展能力， 为国际客户的新药研发项目提供更加高效的支持。目前，英国肯特的实验室仍在积极筹备中。 ...